Breast Cancer, Journal Year: 2023, Volume and Issue: 30(3), P. 364 - 378
Published: Jan. 19, 2023
Language: Английский
Annals of Oncology, Journal Year: 2023, Volume and Issue: 34(8), P. 645 - 659
Published: June 1, 2023
Language: Английский
Citations
157
ESMO Open, Journal Year: 2023, Volume and Issue: 8(4), P. 101592 - 101592
Published: July 4, 2023
•Patients with HER2-low tumours showed better OS than those HER2-zero cancers in both settings.•No differences were found terms of PFS between patients and tumours.•Patients a lower rate pCR compared to cancers. BackgroundHuman epidermal growth factor receptor 2 (HER2)-low expression breast cancer has been recently identified as new therapeutic target. However, it is unclear if status an independent impact on prognosis.Materials methodsA systematic literature research was carried out identify studies comparing survival outcomes affected by versus cancer. Using random-effects models, pooled hazard ratios (HRs) odds (ORs) 95% confidence intervals (CIs) calculated for progression-free (PFS) overall (OS) the metastatic setting well disease-free (DFS), pathological complete response (pCR) early setting. Subgroup analyses hormone (HoR) out. The study protocol registered PROSPERO (n.CRD42023390777).ResultsAmong 1916 records, 42 including 1 797 175 eligible. In setting, associated significant improved DFS (HR 0.86, CI 0.79-0.92, P < 0.001) 0.90, 0.85-0.95, when status. Improved observed HoR-positive HoR-negative populations, while improvement only subgroup. significantly population (OR 0.74, 0.62-0.88, = subgroup 0.77, 0.65-0.90, 0.001). 0.94, 0.89-0.98, 0.008), regardless HoR No found.ConclusionsCompared status, appears be slightly increased advanced settings, expression. seem rates, especially HoR-positive. Human prognosis. A (n.CRD42023390777). Among found. Compared
Language: Английский
Citations
44
Cell Reports Medicine, Journal Year: 2024, Volume and Issue: 5(5), P. 101511 - 101511
Published: April 12, 2024
We present an integrated single-cell RNA sequencing atlas of the primary breast tumor microenvironment (TME) containing 236,363 cells from 119 biopsy samples across eight datasets. In this study, we leverage resource for multiple analyses immune and cancer epithelial cell heterogeneity. define natural killer (NK) heterogeneity through six subsets in TME. Because NK correlates with heterogeneity, characterize at level single-gene expression, molecular subtype, 10 categories reflecting intratumoral transcriptional develop InteractPrint, which considers how influences cancer-immune interactions. use T InteractPrint to predict response checkpoint inhibition (ICI) two clinical trials testing neoadjuvant anti-PD-1 therapy. was predictive both versus PD-L1 (AUC = 0.82, 0.83 vs. 0.50, 0.72). This enables additional high-resolution investigations
Language: Английский
Citations
20
European Journal of Cancer, Journal Year: 2022, Volume and Issue: 173, P. 10 - 19
Published: July 12, 2022
Language: Английский
Citations
63
Frontiers in Oncology, Journal Year: 2022, Volume and Issue: 12
Published: June 16, 2022
Human epidermal growth factor 2 (HER2)-low breast cancer, which is defined as HER2 1+ or 2+ in immunohistochemistry without gene amplification, accounts for a considerable part of all cancers. However, it remains controversial whether HER2-low cancer distinct entity. Our aim was to compare the clinicopathological features and survival outcomes between HER2-zero early cancer.The study retrospective analysis that enrolled 1,039 patients with available expression data single institute from 2013 2014, whom 262 HER2-positive were excluded subsequent analysis. The remaining divided into groups. Each group further categorized hormone receptor (HR)-positive an HR-negative subgroup. Clinicopathological characteristics collected compared primary endpoint disease-free (DFS) overall (OS), analyzed using Kaplan-Meier method log-rank test, landmark analysis, Cox proportional hazards model.A total 777 non-HER2-positive included this 126, 552, 53, 46 HR-positive/HER2-zero, HR-positive/HER2-low, HR-negative/HER2-zero, HR-negative/HER2-low, respectively. No significant difference DFS OS detected when paired by HR status. Landmark time point set at 5 years indicated HR-positive/HER2-low had better HR-positive/HER2-zero after (p = 0.0047). status independent prognostic [hazard ratio (HR) 0.31, 95% confidence interval (CI) 0.13-0.75, p 0.01].The prognosis similar regardless Patients tumors tended have than their counterparts years.
Language: Английский
Citations
48
Cancers, Journal Year: 2022, Volume and Issue: 15(1), P. 126 - 126
Published: Dec. 25, 2022
HER2-low breast cancer (BC) is a newly defined subset of HER2-negative BC that has HER2 immunohistochemical (IHC) score 1+ or 2+/in situ hybridization (ISH) negative phenotype. Recent clinical trials have demonstrated significant benefits novel directing antibody-drug conjugates (ADCs) in treating this group tumors. Trastuzumab-deruxtecan (T-Dxd), HER2-directing ADC was recently approved by the U.S. Food and Drug Administration as first targeted therapy to treat BC. However, still not well characterized clinically pathologically. This review aims update current biological, pathological landscape based on English literature published past two years propose future directions management, pathology practice, translational research We hope it would help better understand tumor biology efforts for identifying recognized targetable
Language: Английский
Citations
47
Cancer Treatment Reviews, Journal Year: 2023, Volume and Issue: 115, P. 102538 - 102538
Published: March 6, 2023
Language: Английский
Citations
41
Therapeutic Advances in Medical Oncology, Journal Year: 2023, Volume and Issue: 15
Published: Jan. 1, 2023
Approximately half of breast cancers (BCs), historically categorized as human epidermal growth factor receptor 2 (HER2)-negative, have low expression HER2 defined an immunohistochemical (IHC) score 1+ or 2+ with negative
Language: Английский
Citations
39
Current Treatment Options in Oncology, Journal Year: 2023, Volume and Issue: 24(5), P. 468 - 478
Published: March 27, 2023
Language: Английский
Citations
34
EBioMedicine, Journal Year: 2023, Volume and Issue: 91, P. 104571 - 104571
Published: April 15, 2023
HER2-low cancers are heterogeneous with different degrees of HER2 expression and hormone receptor (HR) status. Currently, its analysis is mostly focused on the standard clinic-pathologic features or common biomarkers expression, without considering heterogeneity within category. A further characterization understanding this cancer subgroup will facilitate management. large cohort HER2-negative (N = 1464) was included. The 412) HER2-zero 1052) were compared correlated a comprehensive panel clinico-pathologic biomarker according to expressions HR statuses. prognostic values these in also evaluated. characteristics breast cancers, as HER2-zero, varied luminal associated younger age, larger tumor, high pAKT HLA expression. Among TNBCs, opposite trends age tumor size found. Additionally, TNBC showed less necrosis, higher pN, lower c-kit CK14 than cancers. Nonetheless, regardless status, status increased COX2 AR implicated biology HLAs tumors PD-L1 immune cells. In particular, co-expression found be better survival This study revealed characteristic provided insights into prognostication therapeutic strategies. Health Medical Research Fund (08190586), Cheng Yue Pui Charity Foundation CUHK direct grant.
Language: Английский
Citations
31